{"filings":[{"id":90843,"accession_number":"0001193125-26-214680","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Baxter shareholders approve charter amendment and incentive plan; board adopts new executive severance plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved reducing minimum board size to 7 directors; charter amendment filed May 5, 2026.","Shareholders approved Baxter International Inc. Second Amended and Restated 2021 Incentive Plan adding 20M shares.","All nine director nominees elected; advisory vote on executive compensation approved; PwC ratified as auditor for 2026.","Board adopted new Executive Severance and Change in Control Plan effective May 4, 2026, with expanded benefits and tiered structure.","CEO Hider's offer letter amended to increase lump-sum medical coverage from 18 to 24 months in non-CIC termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90842,"accession_number":"0001628280-26-028582","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Baxter Q1 GAAP EPS loss $0.03, adj. $0.36; revenue $2.7B; dividend cut to $0.01","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing operations $2.7B, +3% reported but -1% organic.","GAAP diluted EPS loss of $0.03; adjusted diluted EPS of $0.36.","Quarterly dividend reduced to $0.01 per share, payable July 1 to holders of record May 29.","Company reiterates its full-year 2026 financial outlook.","CEO Andrew Hider says Q1 results in line with expectations; more work remains."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":2701000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100658,"accession_number":"0001193125-26-116114","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Baxter updates on CEO, interim CFO, board refresh, and capital allocation priorities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrew Hider appointed President & CEO in Aug 2025; Brent Shafer named Non-Executive Chair.","Anita Zielinski named interim CFO effective March 2026 following Joel Grade's departure.","Michael McDonnell appointed to the Board and Audit Committee in February 2026.","Targeting net leverage of ~3.0x by end 2026; dividend maintained at $0.01 per share quarterly.","FY 2025 revenue $11.2B; operational sales growth +3%; adjusted diluted EPS +20%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100657,"accession_number":"0001193125-26-107345","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Baxter CFO Joel Grade departs; Anita Zielinski named interim CFO; full-year 2026 outlook reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joel Grade resigns as EVP and CFO effective March 16, 2026, for personal family reasons; advisory role until April 30.","Anita Zielinski, SVP and CAO, appointed interim CFO effective immediately; retains CAO and controller duties.","Zielinski receives $50,000/month interim CFO stipend and $250,000 RSU award vesting over three years.","Baxter reiterates full-year 2026 financial outlook previously issued on February 12, 2026.","Separation agreement provides standard severance under the Executive Severance Plan; departure not due to any disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100656,"accession_number":"0001628280-26-007474","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","8.01","5.02","9.01"],"status":"ready","headline":"Baxter Q4 GAAP EPS loss ($2.01), adj. $0.44; sales $2.97B +8%; div cut to $0.01","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $2.97B (+8% reported, +3% operational); GAAP diluted EPS loss ($2.01), adjusted diluted EPS $0.44.","Board appoints Michael R. McDonnell (former Biogen CFO); directors Cathy Smith and Stephen Rusckowski resign effective Feb 13.","Quarterly dividend declared at $0.01 per share, payable April 1, 2026 to holders of record Feb 27, 2026.","CEO Hider: Q4 results missed expectations; new operating model aims to simplify organization and accelerate innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":11244000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116978,"accession_number":"0000010456-25-000025","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Baxter settles tender offers for up to $600M of 2027 notes and all 2026 notes, purchasing ~$1.04B aggregate","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Early settlement Dec 8: $420.6M of 2.600% 2026 notes and $614.4M of 1.915% 2027 notes purchased.","Late tender for 2026 notes: additional $2.6M accepted at $960.50 per $1,000 plus accrued interest on Dec 22.","2027 notes tender was fully subscribed by early tender date; no additional accepted after.","Tender offers expired Dec 18, 2025; total purchases reduce outstanding principal by over $1.04B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116977,"accession_number":"0001628280-25-055359","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["1.01","8.01","1.02","2.03","9.01"],"status":"ready","headline":"Baxter issues $2B in senior notes; launches tender offers for 2026 and 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $300M 4.450% notes due 2029, $700M 4.900% notes due 2030, and $1B 5.650% notes due 2035.","Net proceeds of ~$1.99B used to repay term loan and fund tender offers for 2026 and 2027 notes.","Tender offers: $420.6M of 2026 notes tendered; $1.089B of 2027 notes tendered, prorated to ~$614.4M accepted.","Repaid all outstanding obligations under Term Loan Credit Agreement on December 4, 2025.","Tender offers priced at fixed spreads: 2026 notes at +30 bps, 2027 notes at +40 bps over UST yields."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116976,"accession_number":"0001628280-25-054015","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Baxter amends credit agreement to raise net leverage cap to 4.25x through Q2 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 1 to five-year credit agreement dated Nov 25, 2025 relaxes net leverage ratio covenant.","Maximum net leverage set at 4.25x for quarters ending Dec 2025, Mar 2026, Jun 2026; 4.00x for Sep 2026; 3.75x thereafter.","JPMorgan Chase is Administrative Agent; multiple banks including Bank of America, Citibank, Deutsche Bank are lenders.","No event of default occurred; representations reaffirmed as of effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116975,"accession_number":"0001628280-25-053187","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Baxter increases tender offer cap for 2027 notes to $600M from $300M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maximum Tender Cap raised to $600M for 1.915% senior notes due 2027, from $300M.","Principal amount outstanding of 2027 notes is $1.45B; offer remains subject to conditions.","Previously announced tender for 2.600% notes due 2026 is unchanged.","Offer modified via press release dated Nov. 19, 2025; dealer managers are Citigroup, BofA, J.P. Morgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116974,"accession_number":"0001628280-25-053056","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Baxter launches tender offers for 2026 and 2027 notes up to $300M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offers to buy any and all of $750M 2.600% 2026 notes and up to $300M of $1.45B 1.915% 2027 notes.","Funding from concurrent senior unsecured notes offering; remaining proceeds to repay $645M term loan.","Early tender deadline Dec 3, 2025; price determination Dec 4; settlement expected Dec 8 or Dec 22.","Tender offers subject to Financing Condition and other terms per the Offer to Purchase.","Citigroup, BofA Securities, J.P. Morgan are dealer managers; D.F. King is tender agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116973,"accession_number":"0001628280-25-051371","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Baxter EVP and Group President Alok Sonig resigns effective December 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alok Sonig, EVP and Group President, Pharmaceuticals, notified Baxter of his resignation on Nov 5, 2025.","Departure effective Dec 1, 2025; Sonig is leaving to join another healthcare company.","No successor for the Pharmaceuticals group president role has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116972,"accession_number":"0001628280-25-047311","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Baxter Q3 2025: sales $2.84B (+5% reported), GAAP EPS loss $0.10, adj. EPS $0.69","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Sales from continuing ops $2.84B, up 5% reported / 2% operational.","GAAP diluted EPS loss $0.10; adjusted diluted EPS $0.69.","Andrew Hider joined as president and CEO, driving continuous improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":8270000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116971,"accession_number":"0001628280-25-045586","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Baxter COO Heather Knight resigns effective Oct 29; CEO to assume interim MPT president role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Knight, EVP and COO, resigns to join another healthcare company; effective Oct 29, 2025.","CEO Andrew Hider will serve as interim group president of Medical Products and Therapies post-departure.","Company will eliminate the COO role effective Oct 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133410,"accession_number":"0001628280-25-036835","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Baxter Q2 2025 sales $2.81B (+4% reported, +1% operational), GAAP EPS $0.24, adj. EPS $0.59, in line with guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales from continuing operations $2.81B, up 4% reported, 1% operational, inline with prior guidance.","GAAP diluted EPS $0.24; adjusted diluted EPS $0.59, both in line with company's previously issued guidance.","Recently announced appointment of Andrew Hider as president and CEO to accelerate innovation and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":5435000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133409,"accession_number":"0001193125-25-155902","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Baxter appoints Andrew Hider as CEO, effective on or before Sept 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment of Andrew Hider as President and CEO, effective on or before Sept 3, 2025.","Hider previously CEO of ATS Corporation; under his leadership ATS revenues nearly doubled over 5 years.","Compensation: base salary $1.35M, target bonus 150% of base, LTI target $14M, sign-on cash $1M and equity awards.","Brent Shafer will transition from Interim CEO to Non-Executive Chair of the Board effective on Effective Date.","Shafer will rejoin Audit and Nominating committees as independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150087,"accession_number":"0001193125-25-139604","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Baxter enters $2.2B amended revolving credit facility and $645M term loan amendment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $2.2B revolver matures June 2030, replacing $2.0B facility and terminating €200M euro facility.","Term loan of $645M extended to December 2027, proceeds used to prepay existing term loan in full.","Revolver adds Baxter Healthcare SA and Baxter World Trade SRL as euro borrowers; up to $300M sublimit for euro borrowings.","Option to increase aggregate commitments by up to $1.1B to $3.3B total.","Covenants include net leverage ratio; interest rates vary by currency and credit rating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150086,"accession_number":"0001628280-25-023809","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Baxter shareholders elect all 10 directors, approve say-on-pay, ratify PwC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ten director nominees elected with majority support; shareholder proposal on stock retention failed.","Advisory say-on-pay vote approved: 405M for, 40M against (~91% of votes cast).","Ratification of PricewaterhouseCoopers as auditor for 2025 approved: 444.5M for, 36.6M against.","Stockholder proposal on executives retaining significant stock did not pass: 165M for, 280M against.","Quorum of ~93.9% of outstanding shares represented at the May 6, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.12,"calibrated_materiality_score":0.12,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150085,"accession_number":"0001628280-25-021320","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Baxter Q1 beats: sales $2.63B, adj. EPS $0.55; FY guidance raised to $2.47-$2.55","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First-quarter sales $2.63B, up 5% reported and operational, exceeding guidance.","GAAP diluted EPS from continuing ops $0.13; adjusted diluted EPS $0.55, both above guidance.","Full-year 2025 adjusted EPS guidance raised: lower end increased to $2.47-$2.55 range.","Chair and interim CEO Brent Shafer cites transformation progress and focus on essential medtech.","Management notes global macroeconomic uncertainty but remains confident in trajectory."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2625000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169087,"accession_number":"0001628280-25-012724","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Baxter provides stockholder engagement presentation; no material new information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation distributed to certain stockholders on March 14, 2025, as part of engagement program.","No specific financial results, M&A, leadership changes, or other material events disclosed.","Exhibit 99.1 text is partial; no concrete forward-looking guidance or operational updates found."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169086,"accession_number":"0001628280-25-006558","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Baxter Q4 adj EPS $0.58 beats guidance; Q4 sales $2.75B (+2% CC)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales from continuing ops $2.75B, up 1% reported / 2% constant currency, exceeding guidance.","GAAP diluted EPS loss ($0.95); adjusted EPS $0.58, ahead of company's guidance range.","Full-year 2024 sales $10.64B (+3% reported & CC); adjusted EPS $1.89, exceeded guidance.","Sale of Kidney Care business completed, streamlining Baxter for next stage of growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":10636000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169082,"accession_number":"0001628280-25-004275","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K/A","filed_at":"2025-02-06T23:59:59+00:00","items":["9.01","7.01"],"status":"ready","headline":"Baxter completes Vantive sale to Carlyle for $3.8B; net proceeds ~$3.4B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed Jan 31, 2025; Baxter received ~$3.71B cash, net after-tax proceeds ~$3.4B.","Pro forma continuing ops net income $275M for 9 months ended Sep 30, 2024; diluted EPS $0.54.","Pro forma balance sheet as of Sep 30, 2024: total assets $25.4B, total equity $7.6B.","Entered into transition services and manufacturing/supply agreements with Vantive post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169085,"accession_number":"0001628280-25-003388","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.01","5.02","9.01"],"status":"ready","headline":"Baxter completes $3.8B sale of kidney care business (Vantive) to Carlyle-backed buyers; net proceeds ~$3.71B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed Jan 31, 2025; net pre-tax cash proceeds of approximately $3.71B after working capital and debt adjustments.","Chris Toth, EVP and Group President Kidney Care, ceased as executive officer effective closing date.","Amendment to purchase agreement clarifies cash adjustment definitions, post-closing cash sweep mechanics, and excess withholding tax exposure.","Original aggregate purchase price of $3.80B in cash, subject to closing adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169084,"accession_number":"0001193125-25-018871","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Baxter CEO Almeida retires; Brent Shafer appointed interim CEO; Heather Knight named COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["José Almeida retired as CEO/Chair effective Feb 3, 2025; will serve as Special Advisor through Oct 31, 2025.","Brent Shafer (former Cerner CEO, Baxter director since 2022) appointed interim CEO and Chair; Board seeks permanent CEO.","Heather Knight named EVP and COO; previously led Medical Products & Therapies segment; reports to interim CEO.","Q4/FY2024 results expected in line with prior continuing ops guidance; earnings call scheduled for Feb 20, 2025.","2025 objectives: 4–5% operational sales growth and ~16.5% adjusted operating margin; tariffs impact not yet included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169083,"accession_number":"0001628280-25-003333","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Baxter appoints Anita Zielinski as Chief Accounting Officer, effective Feb 21, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anita Zielinski, 51, joins from Sysco where she was SVP & CFO of US Foodservice Operations (since 2022).","She previously served as Sysco's SVP & Chief Accounting Officer (2017-2022) and was an audit partner at EY.","Received a sign-on bonus of $150,000 with clawback provisions if employment terminates within 36 months.","Joel Grade will cease as interim CAO/Principal Accounting Officer but remains EVP & CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186159,"accession_number":"0001628280-24-049407","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Baxter amends bylaws: majority voting, exclusive federal forum, stricter advance notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Default voting standard for non-director matters changed to majority of shares entitled to vote (was plurality).","Stockholders using universal proxy rules must comply with SEC rules and provide evidence upon request.","Advance notice requirements enhanced; update deadline reduced to five business days after record date.","Exclusive federal district court forum established for claims under the Securities Act of 1933.","Stockholder soliciting proxies from others must use a proxy color other than white."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186158,"accession_number":"0001628280-24-049002","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Peter Wilver resigns from Baxter board effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wilver resigned for personal reasons; no disagreement with management or Company policies.","Upon resignation, Board size automatically decreases from 12 to 11 directors.","Jeffrey A. Craig, current director, will become Audit Committee chair effective Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186157,"accession_number":"0001628280-24-046501","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Baxter Q3 2024: continuing ops sales +4% to $2.7B; adj. EPS $0.80 beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total sales (incl. discontinued ops) $3.85B; continuing ops sales $2.70B +4% YoY.","GAAP diluted EPS from continuing ops $0.12; adjusted continuing ops EPS $0.49.","Total Baxter GAAP diluted EPS $0.27; adjusted total diluted EPS $0.80, exceeding prior guidance.","North Cove facility restarted highest-throughput IV solutions line after Hurricane Helene.","Pending sale of Kidney Care business is a key milestone; hurricane expected to impact near-term financials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":7883000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186156,"accession_number":"0001628280-24-046016","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Baxter reclassifies Kidney Care as discontinued operations ahead of sale to Carlyle","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Kidney Care business classified as held-for-sale and discontinued operations as of August 2024.","Supplemental unaudited historical financials for Q1 2023 through Q2 2024 restated accordingly.","Transaction with Carlye announced August 12, 2024; closing subject to regulatory approvals.","Prior period financials will be retroactively adjusted to reflect discontinued operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186155,"accession_number":"0001628280-24-042579","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Hurricane Helene forces Baxter to close North Cove facility; aims for 90-100% IV solution allocation by year-end 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["North Cove facility in Marion, NC closed due to unprecedented flooding from Hurricane Helene on Sept 29, 2024; remediation underway.","Baxter implementing customer order allocations based on historical ordering and medical necessity to manage inventory.","Company working with FDA to allow temporary importation of certain products; reallocating capacity from other Baxter facilities.","Goal to restart North Cove production in phases and achieve 90-100% allocation of certain IV solution product codes by end of 2024.","Baxter plans periodic updates on website and will provide financial impact estimate in Q3 2024 earnings announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202784,"accession_number":"0001628280-24-041545","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Baxter's North Cove facility closed after Hurricane Helene flooding; expects negative financial impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["North Cove, N.C. plant closed for production due to flood damage; remediation underway.","Baxter working with FDA, HHS, FEMA, DHS and state officials to resume operations.","Baxter International Foundation committed $1.5M in donations; matching employee donations 2:1.","Allocation process implemented for equitable product distribution; leveraging global network.","Company to provide production restart timing estimate and financial impact update in Q3 earnings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202783,"accession_number":"0001628280-24-039784","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Baxter appoints former Meritor CEO Jeffrey A. Craig to its board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey (Jay) A. Craig appointed to Baxter board effective September 8, 2024; board expands to 12 members.","Craig to serve on Audit Committee; compensated under Non-Employee Director Compensation Plan with prorated equity award for 2024.","Craig previously served as CEO, President, and Executive Chair of Meritor (2015-2021) and earlier as CFO and COO.","He also chairs Hyliion Holdings Corp. and serves on Arcosa Inc.'s audit committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202782,"accession_number":"0001193125-24-212145","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Baxter CAO Brian Stevens resigns; CFO Joel Grade appointed interim CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Stevens resigned as SVP, Chief Accounting Officer and PAO effective Sept 3, 2024; receiving severance per Executive Severance Plan.","Departure not due to any disagreement on operations, policies, financial disclosures or accounting matters.","Joel Grade, EVP & CFO, appointed interim Chief Accounting Officer and PAO, effective same date; compensation unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202781,"accession_number":"0001193125-24-199409","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Baxter agrees to sell Kidney Care segment (Vantive) to Carlyle for $3.8B cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Baxter to receive ~$3.5B in cash; net after-tax proceeds ~$3B; to be used for debt reduction.","Transaction expected close late 2024 or early 2025, subject to regulatory approvals.","Vantive had 2023 revenue of $4.5B and 23,000 employees; Chris Toth to remain as CEO.","Baxter targets 4-5% constant currency operational sales growth post-divestiture; adjusted operating margin ~16.5% for 2025.","Baxter expects to reach below 3.0x leverage by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202780,"accession_number":"0001628280-24-034963","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Baxter Q2 2024 sales $3.81B, adj EPS $0.68 beat; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales from continuing ops $3.81B, up 3% reported, 4% constant currency, beating prior guidance.","GAAP diluted EPS from continuing ops ($0.62); adjusted diluted EPS $0.68, above company's guidance.","Full-year sales growth guidance raised to ~3% (reported and CC); adjusted EPS guidance raised to $2.93-$3.01.","Constant currency growth across all segments; CEO cites momentum from strategic transformation and product launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":7404000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202779,"accession_number":"0001193125-24-181060","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Baxter enters $2.05B credit agreement for refinancing and Kidney Care separation costs","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit Agreement with JPMorgan, BofA, Citibank provides up to $2.05B senior unsecured term loans.","Proceeds to refinance 1.322% Senior Notes due Nov 2024, Floating Rate Notes due Nov 2024, and existing term loan tranche.","Funds also cover U.S. tax liabilities from internal restructuring ahead of planned Kidney Care business separation.","Maturity 364 days from first funding or Nov 24, 2025; includes net leverage ratio covenant.","Ticking fee accrues on undrawn commitments at rate based on Baxter's long-term debt ratings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218954,"accession_number":"0001628280-24-022267","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Baxter shareholders approve officer exculpation amendment and amended 2021 incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected; advisory say-on-pay approved with 86.5% support.","Certificate of incorporation amended to permit officer exculpation under Delaware law (88.9% for).","Amended 2021 Incentive Plan approved, authorizing equity-based awards to employees and officers.","Stockholder proposal on executive stock retention failed (28.9% for, 71.1% against).","Ratification of PricewaterhouseCoopers as independent auditor for 2024 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218953,"accession_number":"0001628280-24-019783","cik":10456,"company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Baxter Q1 2024: sales $3.59B (+3% CC), adj. EPS $0.65, beating guidance; FY2024 adj. EPS guidance $2.88-$2.98","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $3.59B (+2% reported, +3% CC); GAAP EPS $0.07; adj. EPS $0.65, above guidance.","FY 2024 guidance: sales growth ~2% reported, 2-3% CC; adj. EPS $2.88-$2.98.","FDA clearance for Novum IQ large volume infusion pump and Dose IQ Safety Software.","CEO cited solid operational execution and benefits from new operating model."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":3592000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9983345224.411247,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}